MADISON, N.J., Jan. 17 /PRNewswire/ -- Wyeth Consumer Healthcare, a division of Wyeth (NYSE: WYE), supports today's U.S. Food and Drug Administration's (FDA) decision to no longer recommend use of over-the-counter cough and cold products in children under age two.
"This decision is consistent with our voluntary removal in October 2007 of over-the-counter infant cough and cold products from the global market to help reduce dosing errors and overdoses in children who are most vulnerable to misuse of these medicines," says Cavan Redmond, President, Wyeth Consumer Healthcare.
Since October 2007, the Company has worked with retailers, health care
professionals and the FDA to ensure that parents have the information they
need to adapt to the new guidelines regarding use of these medicines in
children under age two.
Wyeth Consumer Healthcare is also taking the following actions:
-- Communicating to healthcare professionals to no longer recommend
over-the-counter cough and cold products for children under age two
-- Changing labels for products that have dosing instructions for
children under age two to clarify that over-the-counter cough and cold
medicines should not be used for children under age two
-- Updating health care professional dosing charts to reflect the new "do
not use" instructions for children under age two
-- Adding the "do not use" instructions for children under age two to
marketing materials for Robitussin and Dimetapp products
It is important to note that Wyeth believes over-the-counter cough and
cold products are safe for use in children ages two and older, as well as
in adults, when used according to label directions
|SOURCE Wyeth Consumer Healthcare|
Copyright©2008 PR Newswire.
All rights reserved